GILD is the most undervalued stock in the biotech space and is making up for dwindling growth by aggressively buying back stock. Last year GILD bought back $15 billion worth of shares and plans to repurchase another $12 billion worth in 2016. Has the money to keep on buying back shares at a rate that gives earnings per share a 10% or more hike annually, a good buy for a stock trading at only 7 times earnings.
GILD is like APPL. They have all the money in the world but can't seem to make an acquisition that would reverse the slide from the slowing down of their biggest money-makers. Until they do, we'll continue to lose money on them. I don't blame people for feeling frustrated.
I listened to the bearish bullet throwers (or should I say bull throwers) once before and missed the boat when aapl split and went through the roof. This time I'm holding, and if it goes to the "lowered" target of 140, I'll be very happy with a nice profit.
My heart will beat faster once the scaredy cats and market manipulators stop playing with this stock.
It probably will. Nine cases were reported out of 613,000, and Gilead had already issued an advisory about taking heart medication along with the drug as a precaution.
Eaton (ETN) Stock Technicals Improve, Chart Indicates 10% Upside
ByBruce KamichFollow | 11/02/15 - 11:15 AM EST
Get TheStreet Quant Ratings' exclusive 5-page report for (ETN) - FREE.
NEW YORK (TheStreet) -- We last discussed Eaton Corp. (ETN - Get Report) on October 21. We said that as prices sank lower in August and September, the momentum readings made higher lows, and this told us that the rate of price declines had slowed. We noted that this is called a bullish divergence and could foreshadow higher prices ahead.
Whether they continue to use some of their billions for stock buybacks or for a transformational M&A, Gilead is a proven winner, beating estimates time after time. The longs will have the last laugh (and the most profits).
Trader Talk, Corporate News, FDAAndroid app on Google Play
FDA Warns of Serious Liver Injury Risk with AbbVie's (ABBV) Viekira Pak
(Updated - October 22, 2015 3:08 PM EDT)
FDA warns of serious liver injury risk with Viekira Pak, according to Bloomberg headlines. The FDA will require Abbvie (NYSE: ABBV) to add new safety risk to its labels.
Peer Gilead Sciences (Nasdaq: GILD) is on watch following the news.
UPDATE - The FDA issued the following safety announcement on Thursday:
The U.S. Food and Drug Administration (FDA) is warning that hepatitis C treatments Viekira Pak and Technivie can cause serious liver injury mostly in patients with underlying advanced liver disease. As a result, we are requiring the manufacturer to add new information about this safety risk to the drug labels.
Nothing. What has changed is the ridiculous over-reaction to Hillary Clinton's comment about controlling drug costs. She's might not even be the nominee, let alone POTUS, and unlikely to get Congress to put a dent in big pharma even if she is elected. Investors who sell a great stock like this on such campaign b.s. are nothing more than a flock of cared sheep who dash off a cliff at the sound of a car horn.